In part one of a 3-part series on the Nitrosamine crisis, Dr.
Andrew Teasdale of AstraZeneca discusses regulatory expectations,
reporting requirements, and minimizing risk relative to solvent
contamination.
About the Podcast
New guidelines from the USP and ICH will facilitate and accelerate adoption of Method Lifecycle Management (MLCM.) Experts will explore a variety of topics to help you understand and adopt MLCM including: key concepts like the Analytical Target Profile, regulatory changes that will impact your workflow, and case studies exploring the application and advantages of MLCM.